Anatara Lifesciences Ltd (AU:ANR) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anatara Lifesciences Ltd has opened patient registration for Stage 2 of its GaRP-IBS clinical trial in Australia, following promising results from Stage 1. The company appointed Dr. Michael West as Chief Scientific Officer to bolster product development and manufacturing. In anticipation of significant trial participation, Anatara aims to update the market on the progress in the upcoming quarter and has hinted at a capital raise following a trading halt announced on April 29, 2024.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.